Longeveron Inc - Class A — Cash Flow (NASDAQ:LGVN)

Financials

Cash from operating activities -9.64 M-13.97 M-19 M-13.87 M-18.64 M -18.64 M Cash from investing activities -10.7 M-677 K8.19 M-640 K-595 K -595 K Cash from financing activities 45.17 M-509 K5.26 M28.79 M4.67 M 4.67 M Free cash flow -10.95 M-14.82 M-19.7 M-14.86 M-19.24 M -19.24 M

News

Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript

Longeveron closes $15 million financing, extends runway to 4Q26

Longeveron secures $15M financing, eyes $15M more on trial results

Longeveron publishes phase 2b stem cell trial results in journal

Longeveron appoints Stephen Willard as new CEO ahead of pivotal trial results

Longeveron receives Japanese patent for stem cell potency assay methods

Longeveron prepares for pivotal HLHS therapy data with FDA meeting

Longeveron receives patent for stem cell therapy targeting female sexual dysfunction

Longeveron executives to speak at CVCT Forum on cell therapy trials

Longeveron receives Canadian patent for stem cell therapy

Longeveron’s stem cell therapy shows reduced neuroinflammation in AD trial

Longeveron to present Alzheimer’s treatment data at CTAD 2025